SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, CAR-T, CD19

July 30, 2021

Gilead Consolidates Their Position as Market Leader; Could Tecartus in R/R Adult ALL Receive A Positive CHMP Opinion By YE 2021? Gilead’s Q2 2021 Earnings Call Summary

Here is a brief preview of this blast: On Thursday, July 29, Gilead held their Q2 2021 earnings call (press release / presentation) highlighting an increase in overall revenue for their cell therapy franchise, while discussing the benefits of a potential FDA approval for Yescarta (CD19 CAR-T) in 2L r/r DLBCL. Furthermore, management highlighted the submission of a Type II variation to the EMA for Tecartus (CD19 CAR-T) in r/r adult ALL. Below, Celltelligence provides insights on how Gilead may leverage Yescarta’s and Tecartus’s expansion into new indications to consolidate their position as a cell therapy market leader, while discussing likely EU approval timelines for Tecartus.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.